Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma

Immune checkpoint inhibitors have achieved unprecedented success in cancer immunotherapy. However, the overall response rate to immune checkpoint inhibitor therapy for many cancers is only between 20 and 40%, and even less for colorectal cancer (CRC) patients. Thus, there is an urgent need to develo...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Front Cell Dev Biol
Autori principali: Fu, Yuyin, Peng, Yujia, Zhao, Shengyan, Mou, Jun, Zeng, Lishi, Jiang, Xiaohua, Yang, Chengli, Huang, Cheng, Li, Yuyan, Lu, Yin, Wu, Mengdan, Yang, Yanfang, Kong, Ting, Lai, Qinhuai, Wu, Yangping, Yao, Yuqin, Wang, Yuxi, Gou, Lantu, Yang, Jinliang
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2021
Soggetti:
Cell and Developmental Biology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8298272/
https://ncbi.nlm.nih.gov/pubmed/34307367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcell.2021.689727
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi